{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:01:12Z","timestamp":1790794872150,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"France Recherche Nord & Sud Sida-HIV H\u00e9patites","award":["Coordinated Action no. 7 (ACT7)"],"award-info":[{"award-number":["Coordinated Action no. 7 (ACT7)"]}]},{"name":"Centre Hospitalier Universitaire de Bordeaux (FR) through the COREVIH Aquitaine,","award":["Inserm (U1219)"],"award-info":[{"award-number":["Inserm (U1219)"]}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The objective of the study was to describe the evolution of chronic non-AIDS related diseases and their risk factors, in patients living with HIV (PLHIV) in the French ANRS CO3 Aquitaine prospective cohort, observed both in 2004 and in 2014 in order to improve long-term healthcare management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The ANRS CO3 Aquitaine cohort prospectively collects epidemiological, clinical, biological and therapeutic data on PLHIV in the French Aquitaine region. Two cross sectional analyses were performed in 2004 and 2014, to investigate the patient characteristics, HIV RNA, CD4 counts and prevalence of some common comorbidities and treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>2138 PLHIV (71% male, median age 52.2\u2009years in 2014) were identified for inclusion in the study, including participants who were registered in the cohort with at least one hospital visit recorded in both 2004 and 2014. Significant increases in the prevalence of diagnosed chronic kidney disease (CKD), bone fractures, cardiovascular events (CVE), hypertension, diabetes and dyslipidaemia, as well as an increase in treatment or prevention for these conditions (statins, clopidogrel, aspirin) were observed. It was also reflected in the increase in the proportion of patients in the \u201chigh\u201d or \u201cvery high\u201d risk groups of the disease risk scores for CKD, CVE and bone fracture score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Between 2004 and 2014, the aging PLHIV population identified in the French ANRS CO3 Aquitaine prospective cohort experienced an overall higher prevalence of non-HIV related comorbidities, including CKD and CVD. Long-term healthcare management and long-term health outcomes could be improved for PLHIV by: careful HIV management according to current recommendations with optimal selection of antiretrovirals, and early management of comorbidities through recommended lifestyle improvements and preventative measures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-05593-4","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T08:19:15Z","timestamp":1605514755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Evolution of comorbidities in people living with HIV between 2004 and 2014: cross-sectional analyses from ANRS CO3 Aquitaine cohort"],"prefix":"10.1186","volume":"20","author":[{"given":"F.","family":"Bonnet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Le Marec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Leleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Gerard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Neau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lazaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Duffau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Caubet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Vandenhende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mercie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cazanave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dabis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"5593_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/QCO.0b013e32835ba6b1","volume":"26","author":"F Nakagawa","year":"2013","unstructured":"Nakagawa F, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis. 2013;26:17\u201325.","journal-title":"Curr Opin Infect Dis"},{"key":"5593_CR2","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","volume":"4","author":"The Antiretroviral Therapy Cohort Collaboration","year":"2017","unstructured":"The Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349\u201356.","journal-title":"Lancet HIV"},{"key":"5593_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/COH.0000000000000298","volume":"11","author":"G Wandeler","year":"2016","unstructured":"Wandeler G, Jonhson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Curr Opin HIVAIDS. 2016;11:492\u2013500.","journal-title":"Curr Opin HIVAIDS"},{"key":"5593_CR4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/QAD.0000000000001335","volume":"31","author":"A Gueler","year":"2017","unstructured":"Gueler A, Moser A, Calmy A, et al. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. AIDS. 2017;31:427\u201336.","journal-title":"AIDS"},{"key":"5593_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/aid.2016.0222","volume":"33","author":"F Goehringer","year":"2017","unstructured":"Goehringer F, Bonnet F, Salmon D, et al. Causes of death in HIV-infected individuals with Immunovirologic. Success in a National Prospective Survey. AIDS Res Hum Retrovir. 2017;33:187\u201393.","journal-title":"AIDS Res Hum Retrovir"},{"key":"5593_CR6","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/cid\/cir626","volume":"53","author":"B Hasse","year":"2011","unstructured":"Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53:1130\u20139.","journal-title":"Clin Infect Dis"},{"key":"5593_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1468-1293.2006.00420.x","volume":"7","author":"G Orlando","year":"2006","unstructured":"Orlando G, Meraviglia P, Cordier L, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med. 2006;7:549\u201357.","journal-title":"HIV Med"},{"key":"5593_CR8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/1471-2334-14-278","volume":"14","author":"PM Luz","year":"2014","unstructured":"Luz PM, Bruyand M, Ribeiro S, et al. AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000-2008: hospital-based cohort studies. BMC Infect Dis. 2014;14:278.","journal-title":"BMC Infect Dis"},{"key":"5593_CR9","doi-asserted-by":"crossref","unstructured":"Smit M, Cassidy R, Cozzi-Lepri A, et al. Quantifying the future clinical burden of an ageing HIV-positive population in Italy: a mathematical modelling study. International Congress of Drug Therapy in HIV Infection 2016, Glasgow. JIAS. 2016;19(suppl 7):120.","DOI":"10.7448\/IAS.19.8.21487"},{"key":"5593_CR10","first-page":"971","volume":"14","author":"R Thiebaut","year":"2000","unstructured":"Thiebaut R, Morlat P, Jacqmin-Gadda H, et al. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidemiologie du SIDA en Aquitaine (GECSA) AIDS. 2000;14:971\u20138.","journal-title":"Groupe d'Epidemiologie du SIDA en Aquitaine (GECSA) AIDS"},{"key":"5593_CR11","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1093\/cid\/civ010","volume":"60","author":"TT Brown","year":"2015","unstructured":"Brown TT, Hoy J, Borderi M, et al. Recommendations for evaluation and Management of Bone Disease in HIV. Clin Infect Dis. 2015;60:1242\u201351.","journal-title":"Clin Infect Dis"},{"key":"5593_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/HJR.0b013e328336a150","volume":"17","author":"N Friis-Moller","year":"2010","unstructured":"Friis-Moller N, Thiebaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehab. 2010;17:491\u2013501.","journal-title":"Eur J Cardiovasc Prev Rehab"},{"key":"5593_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001809","volume":"12","author":"A Mocroft","year":"2015","unstructured":"Mocroft A, Lundgren JD, Ross M, et al. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:a:D study. PLoS Med. 2015;12:e1001809. https:\/\/doi.org\/10.1371\/journal.pmed.1001809.","journal-title":"PLoS Med"},{"key":"5593_CR14","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1093\/cid\/cix212","volume":"64","author":"A Gourlay","year":"2017","unstructured":"Gourlay A, Noori T, Pharris A, et al. The human immunodeficiency virus continuum of Care in European Union Countries in 2013: data and challenges. Clin Inf Dis. 2017;64:1644\u201356.","journal-title":"Clin Inf Dis"},{"key":"5593_CR15","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cid\/ciu701","volume":"59","author":"J Schouten","year":"2014","unstructured":"Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Inf Dis. 2014;59:1787\u201397.","journal-title":"Clin Inf Dis"},{"key":"5593_CR16","volume-title":"Cerebral small-vessel disease in HIV-infected patients well controlled on CART. 17th CROI, Seattle, Washington","author":"A Moulignier","year":"2017","unstructured":"Moulignier A, Savatovsky J, Godin O, et al. Cerebral small-vessel disease in HIV-infected patients well controlled on CART. 17th CROI, Seattle, Washington, 2017. Abstract 75."},{"key":"5593_CR17","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1097\/QAD.0000000000001207","volume":"30","author":"M Shahmanesh","year":"2016","unstructured":"Shahmanesh M, Schultze A, Burns F, et al. The cardiovascular risk management for people living with HIV in Europe: how well are we doing? AIDS. 2016;30:2505\u201318.","journal-title":"AIDS"},{"key":"5593_CR18","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/cid\/civ014","volume":"60","author":"DB Klein","year":"2015","unstructured":"Klein DB, Leyden WA, Xu L, et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis. 2015;60:1278\u201380.","journal-title":"Clin Infect Dis"},{"key":"5593_CR19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s15010-016-0893-z","volume":"44","author":"GV De Socio","year":"2016","unstructured":"De Socio GV, Ricci E, Parruti G, et al. Statins and aspirin use in HIV-infected people: gap between European AIDS clinical society guidelines and clinical practice: the results from HIV-HY study. Infection. 2016;44:589\u201397.","journal-title":"Infection"},{"key":"5593_CR20","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/infdis\/jiw430","volume":"214","author":"KP Reddy","year":"2016","unstructured":"Reddy KP, Parker RA, Losina E, et al. Impact of cigarette smoking and smoking cessation on life expectancy among people with HIV: a US-based modeling study. J Infect Dis. 2016;214:1672\u201381.","journal-title":"J Infect Dis"},{"key":"5593_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153103","volume":"11","author":"S Regan","year":"2016","unstructured":"Regan S, Meigs JB, Grinspoon SK, Triant VA. Determinants of smoking and quitting in HIV-infected individuals. PLoS One. 2016;11:e0153103.","journal-title":"PLoS One"},{"key":"5593_CR22","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.2105\/AJPH.2009.188664","volume":"100","author":"AR Lifson","year":"2010","unstructured":"Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in the strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health. 2010;100:1896\u2013903.","journal-title":"Am J Public Health"},{"key":"5593_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/QAD.0b013e32835b1019","volume":"27","author":"F Bonnet","year":"2013","unstructured":"Bonnet F, Amieva H, Marquant F, et al. Cognitive disorders in HIV-infected patients: are they HIV-related? ANRS CO3 Aquitaine cohort, Bordeaux, France, 2007-2009. AIDS. 2013;27:391\u2013400.","journal-title":"AIDS"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05593-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-05593-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05593-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T08:23:19Z","timestamp":1605514999000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05593-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5593"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05593-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.13503\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13503\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13503\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"13 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Participants provided written informed consent and the study is conducted in compliance with the Helsinki Declaration.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Yes","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Bonnet reports non-financial support from Gilead, Janssen, ViiV healthcare, and MSD, personal fees from Gilead, Janssen, ViiV healthcare, and MSD, outside the submitted work; Dr. Cazanave reports personal fees and non-financial support from Gilead, ViiV Healthcare, and MSD, outside the submitted work; All other authors report nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"850"}}